SAO PAULO (Reuters) – The governor of Brazil’s São Paulo state said on Wednesday that Phase 3 clinical trials of a potential COVID-19 vaccine developed by China’s Sinovac Biotech Ltd have shown promising results and it may be available to Brazilians as early as December.
Some 9,000 Brazilian volunteers are participating in the Sinovac vaccine trials, which are being conducted by the Butantan Institute in Sao Paulo city and 11 other locations, including the capital, Brasilia.
Brazil, which has the third worst outbreak of the novel coronavirus in the world after the United States and India, has become a testing ground for at least two vaccine candidates.
One such vaccine is being developed by AstraZeneca, which has had to pause global trials after an unexplained illness in a participant in Britain.
Trials for the AstraZeneca vaccine on 5,000 volunteers in Brazil are well advanced and have not produced any problems in participants, according to the immunobiology center of Sao Paulo’s Federal University, which is running the trials.
Vaccination of volunteers in Sao Paulo, Rio de Janeiro and Salvador have been put on hold, but work continues monitoring those who have received the first and even the second dose, a university representative said.
At the start of next year, Phase 3 trials of Russia’s “Sputnik-V” COVID-19 vaccine will also be conducted on 10,000 volunteers in Brazil in partnership with the state of Paraná’s Technology Institute, known as Tecpar
Brazilian lab and hospital group DASA SA said on Wednesday it had agreed to conduct Phase 2 and 3 trials in Brazil for a COVID-19 vaccine developed by COVAXX, a unit of privately owned United Biomedical Inc.
On Tuesday, Brazil’s acting Health Minister Eduardo Pazuello said a COVID-19 vaccine would be rolled out for all Brazilians in a mass vaccination starting in January.
SEPTEMBER 9, 2020